Potent antietumor immunity in mice induced by vaccination with an ovine atadenovirus vector

Journal of Immunotherapy

Volumn 35, Issue 1, 2012, Pages 32-41

  Tang, Rongying ^a   Li, Kunyu ^b   Wilson, Michelle ^c   Both, Gerald W ^d   Taylor, John A ^a   Young, Sarah L ^b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c UNIVERSITY OF OTAGO   (New Zealand)

^d Biotech Equity Partners Pty Ltd   (Australia)

Author keywords

adenovirus; immune therapy; T cells; tumor therapy

Indexed keywords

ATADENOVIRUS VECTOR; INTERLEUKIN 12; OVALBUMIN; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG POTENCY; GENE TARGETING; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; UPREGULATION;

ANIMALS; ANTIGENS, NEOPLASM; ATADENOVIRUS; CELL DIFFERENTIATION; CELL PROLIFERATION; DENDRITIC CELLS; GENETIC VECTORS; IMMUNIZATION; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; INTERLEUKIN-12; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; OVALBUMIN; SHEEP; TUMOR BURDEN;

EID: 84155167176     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e318238a115     Document Type: Article

References (40)

1. Bowen GP, Borgland SL, Lam M, et al. Adenovirus vector-induced inflammation: capsid-dependent induction of the C-C chemokine RANTES requires NFkB. Hum Gene Ther. 2002;13:367-379.
2. Zaiss A, Liu Q, Bowen GP, et al. Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J Virol. 2002;76:4580-4590.
3. Molinier-Frenkel V, Le Boulaire C, Le Gal FA, et al. Longitudinal follow-up of cellular and humoral immunity induced by recombinant adenovirus-mediated gene therapy in cancer patients. Hum Gene Ther. 2000;11:1911-1920.
4. Santra S, Seaman MS, Xu L, et al. Replication-defective aenovirus serotype 5 vectors elicit cellular and humoral immune responses in nonhuman primates. J Virol. 2005;79: 6516-6522.
5. Osada T, Yang XY, Venturi B, et al. A novel non-replicating adenoviral vector expressing carcinoembryonic antigen (CEA) breaks tolerance to CEA in CEA-transgenic mice. Proc Am Ass Cancer Res. 2004;45.
6. Salucci V, Mennuni C, Calvaruso F, et al. CD8+ T cell tolerance can be broken by an adenoviral vaccine while CD4+ T-cell tolerance is broken by additional co-administration of a Toll-like receptor ligand. Scand J Immunol. 2006;63:35-41.
7. Liber A, He C, Meuse L, et al. The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J Virol. 1997;71: 8798-8807.
8. McCaffrey AP, Fawcett P, Nakai H, et al. The host responses to adenovirus, helper-dependent adenovirus, and adeno-associated virus in mouse liver. Mol Ther. 2008;16:931-941.
9. Roberts D, Nanda A, Havenga M, et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature. 2006;441:239-243.
10. Sumida SM, Truitt DM, Kishko MG, et al. Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. J Virol. 2004;78:2666.
11. Mast TC, Kierstead L, Gupta SB, et al. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titres and implications for potential HIV vaccine trials. Vaccine. 2009;28:474-483.
12. Boyle DB, Pye AD, Kocherhans R, et al. Characterisation of Australian ovine adenovirus isolates. Vet Microbiol. 1994;41: 281-291.
13. Both GW. Ovine atadenovirus: a review of its biology, biosafety profile and application as a gene delivery vector. Immunol Cell Biol. 2004;82:189-195.
14. Xu ZZ, Both GW. Altered tropism of an ovine adenovirus carrying the fiber protein cell binding domain of human adenovirus type 5. Virology. 1998;248:156-163.
15. Khatri A, Xu ZZ, Both GW. Gene expression by atypical recombinant ovine adenovirus vectors during abortive infection of human and animal cells in vitro. Virology. 1997;239: 226-237.
16. Both GW. Identification of a unique family of F-box proteins in atadenoviruses. Virology. 2002;304:425-433.
17. Kumin D, Hofmann C, Rudolph M, et al. Biology of ovine adenovirus infection of nonpermissive cells. J Virol. 2002;76: 10882-10893.
18. Lockett LJ, Both GW, Lockett LJ, et al. Complementation of a defective human adenovirus by an otherwise incompatible ovine adenovirus recombinant carrying a functional E1A gene. Virology. 2002;294:333-341.
19. Wuest T, Both GW, Prince AM, et al. Recombinant ovine atadenovirus induces a strong and sustained T cell response against the hepatitis C virus NS3 antigen in mice. Vaccine. 2004;22:2717-2721.
20. Hofmann C, Loser P, Cichon G, et al. Ovine adenovirus vectors overcome preexisting humoral immunity against human adenoviruses in vivo. J Virol. 1999;73:6930-6936.
21. Bridgeman A, Roshorm Y, Lockett LJ, et al. Ovine atadenovirus, a novel and highly immunogenic vector in prime-boost studies of a candidate HIV-1 vaccine. Vaccine. 2010;28:950-957. [Epub 2009].
22. Both GW, Cameron F, Collins A, et al. Production and release testing of ovine atadenovirus vectors. Methods Mol Med. 2007;130:69-90.
23. Fraser CK, Diener KR, Lousberg EL, et al. Inducing potent cellular and humoral immunity following a rational prime-boost immunisation regimen incorporating recombinant ovine atadenovirus and fowlpox virus. Clin Vaccine Immunol. 2010;17:1679-1686.
24. Faulkner L, Buchan G, Lockhart E, et al. IL-2 linked to a peptide from influenza hemagglutinnin enhances T cell activation by affecting the antigen-presentation function of bone marrow-derived dendritic cells. Int Immunol. 2001;13: 713-721.
25. Ritchie DS, Hermans IF, Lumsden JM, et al. Dendritic cell elimination as an assay of cytotoxic T lymphocyte activity in vivo. J Immunol Methods. 2000;246:109-117.
26. Korst RJ, Mahtabifard A, Yamada R, et al. Effect of adenovirus gene transfer vectors on the immunologic functions of mouse dendritic cells. Mol Ther. 2002;5:307-315.
27. den Boer AT, Diehl L, van Mierlo GJ, et al. Longevity of antigen presentation and activation status of APC are decisive factors in the balance between CTL immunity versus tolerance. J Immunol. 2001;167:2522-2528.
28. Liu L, Rich BE, Inobe J, et al. Induction of Th2 cell differentiation in the primary immune response: dendritic cells isolated from adherent cell culture treated with IL-10 prime naive CD4+ T cells to secret IL-4. Int Immunol. 1998;10: 1017-1026.
29. Liu Q, Muruve DA. Molecular basis of the inflammatory response to adenovirus vectors. Gene Ther. 2003;10: 935-940.
30. Adams WC, Bond E, Havenga MJ, et al. Adenovirus serotype 5 infects human dendritic cells via coxaskievirus-adenovirus receptor-independent receptor pathway mediated by lactofer-rin and DC-SIGN. J Gen Virol. 2009;90:1600-1610.
31. Manetti R, Parronchi P, Giudizi MG, et al. Natural killer cell stimulatory factor (IL-12) induces T helper type 1 (Th1)-specific immune response and inhibits the development of IL-4-producing Th cells. J Exp Med. 1993;177:1199-1204.
32. Burgert HG, Kvist S. An adenovirus type 2 glycoprotein blocks cell surface expression of human histocompatibility class I antigens. Cell. 1985;41:987-997.
33. Vrati S, Boyle D, Kocherhans R, et al. Sequence of ovine adenovirus homologs for 100K hexon assembly, 33K, pVIII, and fiber genes: early region E3 is not in the expected location. Virology. 1995;209:400-408.
34. Macatonia SE, Hosken NA, Litton M, et al. Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. J Immunol. 1995;154:5071-5079.
35. McKnight AJ, Zimmer GJ, Fogelman I, et al. Effects of IL-12 on helper T cell-dependent immune response in vivo. J Immunol. 1994;152:2172-2179.
36. Demangel C, Bertolino P, Britton WJ. Autocrine IL-10 impairs dendritic cell (DC)-derived immune responses to mycobacterial infection by suppressing DC trafficking to draining lymph nodes and local IL-12 production. Eur J Immunol. 2002;32: 994-1002.
37. Curtsinger JM, Lins DC, Mescher MF. Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J Exp Med. 2003;187:1141-1151.
38. Tatsis N, Fitzgerald JC, Reyes-Sandoval A, et al. Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines. Blood. 2007;110: 1916-1923.
39. Finn JD, Bassett J, Millar JB, et al. Persistence of transgene expression influences CD8+ T-cell expansion and maintenance following immunization with recombinant adenovirus. J Virol. 2009;83:12027-12036.
40. Ko H, Kim YH, Kim YS, et al. A combination of chemo-immunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res. 2007;67:7479-7486.